🩺 Beyond Diabetes, Beyond Albuminuria, Beyond Expectations: Finerenone Across the CKD Spectrum

🚀 Major advance in nephrology and cardiorenal medicine!   The INFINITY pooled analysis (14,574 participants) demonstrates that finerenone reduces CKD progression, kidney failure, heart failure hospitalization, cardiovascular death, and even all-cause mortality across a broad spectrum of chronic kidney disease—not just type 2 diabetes. 🩺❤️🩺   Benefits were remarkably consistent across glycemic status, CKD etiology, eGFR, albuminuria, and SGLT2 inhibitor use. Hyperkalemia remains the key safety consideration but serious events were uncommon.   Could finerenone become a foundational therapy for CKD regardless of diabetes status? 🔬📈   #CKD #Nephrology #Cardiology #Finerenone #CardioRenal #MedicalPodcasts #INFINITYTrial #KidneyDisease #HeartFailure #PrecisionMedicine